By eliminating METTL3-mediated FOXO3 mRNA stabilization in the hypoxic tumor microenvironment, METTL3 depletion significantly enhanced the drug resistance of HCC to sorafenib, which confirmed FOXO3 as a crucial m6A modification downstream molecule in the sorafenib resistance of HCC [80]. This evidence concerns the gene FOXO3 and neoplasm.